News | May 10, 2007

St. Jude’s OptiSense Lead Provides Unique “Smart” Pacing

May 11, 2007 — St. Jude Medical Inc. has announced FDA approval of its new OptiSense lead, a first-of-its-kind "smart" pacing lead designed to offer more accurate sensing in the upper chamber of the heart (right atrium).

The lead incorporates a new tip design that reduces extraneous signals from the heart's lower chambers (ventricles) that can interfere with a pacemaker's sensing mechanism and disrupt optimal therapy.

The OptiSense lead's improved sensing of desired electrical signals in the atria allows physicians more flexibility in programming atrial sensitivity settings while avoiding sensing signals from the ventricles. This allows for more accurate detection of impulses from the patient's atrium.

Reducing the detection of unwanted signals, the OptiSense lead may also provide physicians greater freedom in lead placement options. Leads may be able to be placed in areas, such as the lower inner atrium, that may be optimal for pacing, but that may have previously been ruled out because of interfering signals from the heart's lower chambers.

The improved sensing performance of the OptiSense lead is a result of an innovative 1.1 mm tip-to-ring spacing, which reduces oversensing of far-field R-wave signals (an electrical signal originating in the lower chamber of the heart and sensed by the lead in the upper chamber of the heart).

Conclusion highlights from the OptiSense Lead Clinical Study, which were presented during the Featured Poster Session at the Heart Rhythm 2007 meeting on May 9, include:

• The OptiSense lead had no evidence of paced far-field signals in 90.9 percent of patients compared to 40.9 percent of the control patients (p less than 0.0001).

• The OptiSense lead group exhibited a highly statistically significant reduction (p = 0.03) in the percentage of patients in appropriate mode switching (6.9 percent of OptiSense patients versus 25.7 percent of control group patients) as well as a highly statistically significant reduction (p = 0.009) in the percentage of episodes of inappropriate mode switching (3 percent versus 49 percent). Inappropriate mode switching is not desirable because, if it occurs, it can cause a loss of synchrony between the upper and lower chambers of the heart.

For more information visit www.sjm.com.


Related Content

News | Pacemakers

June 1, 2023 — Every year more than one million people receive a pacemaker. Until now, leadless versions were only ...

Home June 01, 2023
Home
News | Pacemakers

May 25, 2023 — Abbott announced late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device ...

Home May 25, 2023
Home
News | Pacemakers

May 12, 2023 — Biotronik, a leading global medical technology company with 60 years of experience in developing trusted ...

Home May 12, 2023
Home
News | Pacemakers

May 1, 2023 — Medtronic plc, a global leader in healthcare technology, announced it has received U.S. Food and Drug ...

Home May 01, 2023
Home
News | Pacemakers

December 12, 2022 — The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between ...

Home December 12, 2022
Home
News | Pacemakers

June 9, 2022 — Holes help make sponges and English muffins useful (and, in the case of the latter, delicious). Without ...

Home June 09, 2022
Home
News | Pacemakers

April 5, 2022 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber ...

Home April 05, 2022
Home
News | Pacemakers
February 16, 2022 – A revolutionary pacemaker that re-establishes the heart’s naturally irregular beat is set to be ...
Home February 16, 2022
Home
News | Pacemakers

August 9, 2021 — Boston Scientific is recalling INGENIO family of pacemakers and CRT-Ps due to the risk of incorrect ...

Home August 09, 2021
Home
News | Pacemakers

June 16, 2020 - Biotronik has today announced its commitment to giving physicians additional tools to pace in the His ...

Home June 16, 2020
Home
Subscribe Now